224 related articles for article (PubMed ID: 22847606)
21. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
22. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.
Zhu K; Zhao Q; Yue J; Shi P; Yan H; Xu X; Wang R
Oncotarget; 2016 Oct; 7(42):68328-68338. PubMed ID: 27634904
[TBL] [Abstract][Full Text] [Related]
23. A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer.
Dalle Fratte C; Mezzalira S; Polesel J; De Mattia E; Palumbo A; Buonadonna A; Palazzari E; De Paoli A; Belluco C; Canzonieri V; Toffoli G; Cecchin E
Oncol Res; 2022 Jan; 28(9):847-855. PubMed ID: 34108073
[TBL] [Abstract][Full Text] [Related]
24. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
25. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Konishi T; Shinozaki E; Murofushi K; Taguchi S; Fukunaga Y; Nagayama S; Fujimoto Y; Akiyoshi T; Nagasaki T; Suenaga M; Chino A; Kawachi H; Yamamoto N; Ishikawa Y; Oguchi M; Ishizuka N; Ueno M; Yamaguchi K
Ann Surg Oncol; 2019 Aug; 26(8):2507-2513. PubMed ID: 30963400
[TBL] [Abstract][Full Text] [Related]
26. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
27. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
D'Alterio C; Avallone A; Tatangelo F; Delrio P; Pecori B; Cella L; Pelella A; D'Armiento FP; Carlomagno C; Bianco F; Silvestro L; Pacelli R; Napolitano M; Iaffaioli RV; Scala S
Int J Cancer; 2014 Jul; 135(2):379-90. PubMed ID: 24375277
[TBL] [Abstract][Full Text] [Related]
28. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
[TBL] [Abstract][Full Text] [Related]
29. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy.
Yan H; Yu J; Wang R; Jiang S; Zhu K; Mu D; Xu Z
Med Oncol; 2012 Mar; 29(1):168-73. PubMed ID: 21264534
[TBL] [Abstract][Full Text] [Related]
31. [Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
Richter I; Dvořák J; Blüml A; Cermáková E; Bartoš J; Urbanec M; Sitorová V; Ryška A; Sirák I; Buka D; Ferko A; Melichar B; Petera J
Klin Onkol; 2014; 27(5):361-6. PubMed ID: 25312714
[TBL] [Abstract][Full Text] [Related]
32. Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway.
Yu Z; Zhang C; Wang H; Xing J; Gong H; Yu E; Zhang W; Zhang X; Cao G; Fu C
Cancer Lett; 2014 Oct; 353(2):182-93. PubMed ID: 25088576
[TBL] [Abstract][Full Text] [Related]
33. Poor prognostic and staging value of tumor deposit in locally advanced rectal cancer with neoadjuvant chemoradiotherapy.
Wang Y; Zhang J; Zhou M; Yang L; Wan J; Shen L; Liang L; Yao Y; Zhang H; Zhang Z
Cancer Med; 2019 Apr; 8(4):1508-1520. PubMed ID: 30790459
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation.
Ruby JA; Leibold T; Akhurst TJ; Shia J; Saltz LB; Mazumdar M; Riedel ER; Larson SM; Guillem JG
Dis Colon Rectum; 2012 Apr; 55(4):378-86. PubMed ID: 22426260
[TBL] [Abstract][Full Text] [Related]
35. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
[TBL] [Abstract][Full Text] [Related]
36. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
Wolthuis AM; Penninckx F; Haustermans K; De Hertogh G; Fieuws S; Van Cutsem E; D'Hoore A
Ann Surg Oncol; 2012 Sep; 19(9):2833-41. PubMed ID: 22451236
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression.
Sowa T; Menju T; Chen-Yoshikawa TF; Takahashi K; Nishikawa S; Nakanishi T; Shikuma K; Motoyama H; Hijiya K; Aoyama A; Sato T; Sonobe M; Harada H; Date H
Cancer Med; 2017 Jan; 6(1):288-297. PubMed ID: 28028936
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.
Park IJ; You YN; Agarwal A; Skibber JM; Rodriguez-Bigas MA; Eng C; Feig BW; Das P; Krishnan S; Crane CH; Hu CY; Chang GJ
J Clin Oncol; 2012 May; 30(15):1770-6. PubMed ID: 22493423
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Inoue Y; Uchida K; Mohri Y; Kusunoki M
Oncol Rep; 2012 Sep; 28(3):855-61. PubMed ID: 22711167
[TBL] [Abstract][Full Text] [Related]
40. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]